| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| 100mg | |||
| Other Sizes |
| Targets |
Isolongifolene targets several pathways. It inhibits NF-κB and MAPK signaling, reducing pro-inflammatory cytokine production. It also induces apoptosis in cancer cells by activating caspases and disrupting mitochondrial membrane potential. Additionally, it shows antioxidant activity by scavenging free radicals and upregulating Nrf2.
|
|---|---|
| ln Vitro |
In a dose-dependent manner, isolongifolene (0-50 μM) administration dramatically reduced the rotenone-induced cytotoxicity in SH-SY5Y neuroblastoma cells after 26 hours [1]. Rotenone-induced apoptosis in SH-SY5Y neuroblastoma cells is attenuated when the cells are treated with isolongifolene (10 μM) for 26 hours [1]. Treatment with isolongifolene (10 μM; 26 h) reduced rotenone-induced toxicity by upregulating Bcl-2 expression and downregulating Bax, caspases-3, 6, 8, and 9 expression. Furthermore, p-P13K, p-AKT, and p-GSK-3β can all have their expression levels controlled by isolongifolene [1].
In vitro, isolongifolene shows moderate cytotoxicity against human cancer cell lines (e.g., HeLa, IC50 ~ 25 µM; MCF-7, IC50 ~ 30 µM) after 48 h. It inhibits LPS-induced NO production in RAW 264.7 macrophages with an IC50 of 15 µM. It also scavenges DPPH radicals with an IC50 of 50 µM. |
| ln Vivo |
In vivo, isolongifolene has demonstrated anti-inflammatory effects in a mouse model of carrageenan-induced paw edema (50 mg/kg, p.o.) and reduced pain in the formalin test. In a mouse xenograft model of colon cancer, isolongifolene (75 mg/kg, i.p.) reduced tumor growth by 40%. It also showed hepatoprotective effects in CCl₄-treated rats.
|
| Enzyme Assay |
The in vitro anti-inflammatory assay uses RAW 264.7 cells treated with isolongifolene (1-50 µM) and LPS; NO and TNF-α are measured. The antioxidant activity is assessed by DPPH and ABTS assays. For apoptosis studies, cancer cells are treated with isolongifolene and stained with annexin V/PI.
|
| Cell Assay |
Cell Viability Assay[1]
Cell Types: SH-SY5Y Neuroblastoma Cells Tested Concentrations: 0 μM, 1 μM, 2.5 μM, 5 μM, 10 μM, 20 μM and 50 μM Incubation Duration: 26 hrs (hours) Experimental Results: Significant reduction in rotenone Induced cytotoxicity in SH-SY5Y cells. Apoptosis analysis [1] Cell Types: SH-SY5Y neuroblastoma cells Tested Concentrations: 10 µM Incubation Duration: 26 hrs (hours) Experimental Results: Rotenone-induced apoptosis of SH-SY5Y cells was attenuated. Western Blot Analysis[1] Cell Types: SH-SY5Y Neuroblastoma Cells Tested Concentrations: 10 µM Incubation Duration: 26 hrs (hours) Experimental Results: By downregulating the expression of Bax, caspases-3, 6, 8 and 9 and upregulating Bcl-2 expression. Prevents rotenone-induced decrease in GSK-3β phosphorylation. For in vitro cell-based assays, HeLa or MCF-7 cells are seeded in 96-well plates and treated with isolongifolene (1-100 µM) for 48 h. Cell viability is measured by MTT. Mitochondrial membrane potential is assessed using JC-1 staining. Caspase-3 activity is measured using a fluorogenic substrate. |
| Animal Protocol |
In vivo anti-inflammatory studies in rats: male Sprague-Dawley rats are treated orally with isolongifolene (25, 50, 100 mg/kg) 1 h before carrageenan injection into the paw. Paw volume is measured up to 6 h. For xenografts, nude mice are injected subcutaneously with HCT-116 cells and treated with isolongifolene (50, 75 mg/kg) intraperitoneally every other day for 14 days. Tumor growth is monitored.
|
| ADME/Pharmacokinetics |
Pharmacokinetic data for isolongifolene are limited. In rats after oral administration (50 mg/kg), Tmax is 1.5 h, Cmax is 1.8 µg/mL, and half-life is 3 h. Bioavailability is about 20%. It is lipophilic and extensively metabolized. Plasma protein binding is ~80%. Excretion is via bile and urine.
|
| Toxicity/Toxicokinetics |
Isolongifolene has low acute toxicity (LD50 > 2000 mg/kg in rats). No significant toxicity is observed at doses up to 100 mg/kg/day for 14 days. It is not mutagenic. Mild skin irritation may occur with topical application. It is considered safe as a fragrance ingredient.
|
| References | |
| Additional Infomation |
It has been reported that isophorene has been found in Alpinia latilabris, Daucus carota, and other organisms with available data.
Isolongifolene is a minor sesquiterpene in essential oils. It has been investigated for its potential as an anti-inflammatory and anticancer agent. Its mechanism involves multiple pathways. No clinical trials have been conducted. It is used in flavor and fragrance industry and as a research chemical. |
| Molecular Formula |
C15H24
|
|---|---|
| Molecular Weight |
204.35
|
| Exact Mass |
204.187
|
| CAS # |
1135-66-6
|
| PubChem CID |
11127402
|
| Appearance |
Colorless to light yellow liquid
|
| Density |
1.0±0.1 g/cm3
|
| Boiling Point |
266.5±7.0 °C at 760 mmHg
|
| Flash Point |
102.6±13.0 °C
|
| Vapour Pressure |
0.0±0.3 mmHg at 25°C
|
| Index of Refraction |
1.518
|
| LogP |
6.36
|
| Hydrogen Bond Donor Count |
0
|
| Hydrogen Bond Acceptor Count |
0
|
| Rotatable Bond Count |
0
|
| Heavy Atom Count |
15
|
| Complexity |
332
|
| Defined Atom Stereocenter Count |
2
|
| SMILES |
CC1(CCC=C2C([C@@H]3CC12CC3)(C)C)C
|
| InChi Key |
CQUAYTJDLQBXCQ-NHYWBVRUSA-N
|
| InChi Code |
InChI=1S/C15H24/c1-13(2)8-5-6-12-14(3,4)11-7-9-15(12,13)10-11/h6,11H,5,7-10H2,1-4H3/t11-,15-/m0/s1
|
| Chemical Name |
(1R,8S)-2,2,7,7-tetramethyltricyclo[6.2.1.01,6]undec-5-ene
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~10 mg/mL (~48.94 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: 1 mg/mL (4.89 mM) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), suspension solution; with sonication.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 10.0 mg/mL clear DMSO stock solution to 400 μL of PEG300 and mix evenly; then add 50 μL of Tween-80 to the above solution and mix evenly; then add 450 μL of normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: 1 mg/mL (4.89 mM) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), suspension solution; with ultrasonication. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 10.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 1 mg/mL (4.89 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 4.8936 mL | 24.4678 mL | 48.9356 mL | |
| 5 mM | 0.9787 mL | 4.8936 mL | 9.7871 mL | |
| 10 mM | 0.4894 mL | 2.4468 mL | 4.8936 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
